Gregg Tobin on Aptyx’s latest deal and trends in medtech

Aptyx President and CEO Gregg Tobin [Photo courtesy of Aptyx]

Aptyx has been making a name for itself as a contract development and manufacturing organization focused on minimally invasive medtech.

Known as Molded Devices Inc. (MDI) before its sale to private equity firm TruArc Partners, Tempe, Arizona-based Aptyx rebranded in 2023 and grew with two deals in 2025. In January, Aptyx purchased Medical Murray’s Charlotte, North Carolina, operation, and then bought Argos Corp. near Boston in December.

When we interviewed Aptyx President and CEO Gregg Tobin about the latest deal, we also asked for his perspective on medtech trends, his advice for working with outsourcing partners, and his predictions for 2026. The following has been lightly edited for space and clarity.

MDO: What are your predictions for the year ahead?

Tobin: “It’s going to be another good year of growth for for Aptyx. I think you’re going to see stable growth within medical devices around the world. I love the innovation that’s happening in several different interventional segments. I love what’s happening in robotic surgery. There’s just a tremendous amount of innovation that’s occurring. OEMs see the value of investing in R&D, and they’re seeing the value of these breakthrough technologies. They’re very possible. You just have to stay the course and focus on getting good clinical efficacy.”

MDO: What kind of work do you do with surgical robotics developers?

Intermeshing gears [Photo courtesy of Aptyx]

Tobin: “Any robotic surgical platform in the market today should know of us, and should we should know them. … We’ve got so much expertise in robotic surgery in terms of developing gears and gear assemblies that enable the precision that’s needed in robotic surgery. I foresee a continued conversion from metal to plastic and with the advanced materials and advanced molding capabilities we have, we can really provide a superior solution for our customers.”

MDO: Are you expecting competition to intensify for medtech customers like yours?

Tobin: “There’s healthy competition and it will definitely continue. The good news for us is we’re scaling, we’re creating breadth, we’re becoming one of the larger players now globally, so I think we’re in a really strong position. It’s going to be more challenging for some of the smaller CMOs and CDMOs over time because companies like Aptyx are going to continue to scale and add breadth and capabilities.”

MDO: I’m hearing contract manufacturers that are diversified in other industries like automotive and consumer are putting more resources into their medtech businesses for its resilience in soft economies. Are you expecting moves like that from the larger CMOs?

Tobin: “I would not be surprised if what you’re describing materializes. If you look at the prevalence and incidence of disease around the world, it’s continuing at a reasonable rate. That’s fueling the demand for medical devices, it’s fueling the demand for innovation, and it’s going to continue to persist for the next couple of decades. If companies want to invest in this sector, they can expect attractive returns. For that reason, I think what you’re hearing is accurate and plausible now.”

MDO: I was just talking with a product development engineer at a major OEM who said because big companies like his can be demanding, he was curious to know if there’s anything OEMs can do to be better customers and easier to work with?

Tobin: “When I think about our relationship with our OEMs, we’re here to make them better. We’re not the adversary. We understand they need to become ever more profitable, and they’ve got to have efficacious products. My message would be: Trust your suppliers — the suppliers that you’re comfortable with. They have your best interests at heart, and we do the right thing for our customers. Demanding is fine. I do like to be challenged. We hold high standards for ourselves, but we’re here to support the success of our OEMs. We’re here to make them win.”

MDO: Do you have any advice to help device developers find and vet CMOs and CDMOs?

Tobin: “Keep an open mind and be curious about what the various CDMOs can can offer. We’re investing in engineering expertise, we’re investing in continuous improvement, we’re investing in training, and we’re investing to become world class. We want to be an extension of our customers so we look more like them. I would encourage the OEMs to seek out those characteristics in in a partner CDMO.”

MDO: What changes do you have in store for the Argos Corp. business Aptyx just purchased?

Aptyx’s new Precision Extrusion Center of Excellence’s capabilities at its Argos Corp. facility include high-precision tubing. [Photo courtesy of Aptyx]

Tobin: “We love the team, highly, highly engineered, highly experienced. We would not have made the investment without the team, and the team will only get larger. The plan is to invest in our friends, our new colleagues at Argos and help them become even more efficient and support capacity. We’re already working with them to make investments in the location. Bigger, stronger, faster.”

MDO: What sort of employees will you be hiring for that team?

Tobin: “We’re always in the market for engineers, extrusion engineers, project managers. Those are probably the most desirable roles in the short run. People with experience in in plastics, in extrusion and project management, we would love to hear from them.”

MDO: After this deal, what are you looking for next? What else do you need to add to your company’s capabilities?

Tobin: “I’m really pleased with what we’ve built over the last three years. We have a nice complement. The focus going forward is positioning this most effectively with our large OEM customers and ensuring we understand their pain points. We’re supporting them through molding services, through extrusion, through building finished devices in the U.S. and Mexico and Asia. We’ve got a global footprint now so we can support our customers’ growth around the world, across several different technologies and in several different business units.”

MDO: What are you’re seeing in the interventional and catheter-based device space that motivated you to do this deal and got you so focused on this market?

Tobin: “The need for continued innovation. When you think about implants, those are solving unmet needs and taking innovative approaches to lower morbidity and improve patient outcomes. To launch these new innovations into the market, our customers need resources, engineering, product development. We bring all of those services to support them in more rapidly bringing their products to market.”

MDO Min-Vasive Medtech: Download our free 72-page special report featuring interviews with minimally invasive device development experts and engineers at major OEMs and groundbreaking startups